The results of prostate carcinoma screening in the U.S. as reflected in the Surveillance, Epidemiology, and end results program : Review of current data impacting early detection guidelines for prostate cancer.
American Cancer Society Workshop. Phoenix, Arizona (USA), 1997/03/10.
The rapid escalation in the incidence of prostate carcinoma between the years 1988 and 1992 has been attributed to prostate specific antigen screening.
There have been concerns regarding the possible diagnosis and treatment of insignificant tumors in the absence of randomized, controlled trial evidence of a decrease in mortality.
Descriptive studies suggest that serial screening decreases the detection of advanced disease.
In November 1996, the National Center for Health Statistics recorded a decrease in prostate carcinoma mortality.
The basis of this analysis is 208,234 prostate carcinoma cases diagnosed between 1973 and 1993 in population-based Surveillance, Epidemiology, and End Results registries.
The general staging system was used rather than that of the American Joint Committee on Cancer to permit observation of long term trends.
Grade incorporating Gleason scores was used as an indication of the significance of the prostate carcinoma.
Age-adjusted survival rates were used to separate prostate carcinoma deaths from deaths due to other causes.
The increase in the incidence of prostate carcinoma has been greater than for any other malignancy.
The increase was largely in Grade 2 significant tumors and not in Grade 1 (15%) insignificant tumors.
There was a decrease in the detection of advanced disease.
After the peak incidence in 1992, a progressive decrease to near baseline levels occurred. (...)
Mots-clés Pascal : Carcinome, Prostate, Homme, Dépistage, Programme sanitaire, Résultat, Pronostic, Epidémiologie, Analyse tendance, Etats Unis, Amérique du Nord, Amérique, Tumeur maligne, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie
Mots-clés Pascal anglais : Carcinoma, Prostate, Human, Medical screening, Sanitary program, Result, Prognosis, Epidemiology, Trend analysis, United States, North America, America, Malignant tumor, Male genital diseases, Urinary system disease, Prostate disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0027651
Code Inist : 002B14D02. Création : 17/04/1998.